Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04770545
Other study ID # APL2-GA-305
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date March 4, 2021
Est. completion date September 2025

Study information

Verified date August 2023
Source Apellis Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1200
Est. completion date September 2025
Est. primary completion date September 2025
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: Ocular-specific inclusion criteria apply to the study eye only. - Subjects must have participated in APL2-103 (NCT03777332) or completed the treatment at Month 24 of either APL2-303 (Derby, NCT03525613) or APL2-304 (Oaks, NCT03525600). - For subjects who participated in either the 303 or 304 studies, the condition listed below must also be met for participating in this study. - Subjects who did not fully stop study drug treatment, but missed the visit at Month 24, can also participate in the study. However, to participate, subjects must be seen within 60 days from the last day of the period allowed for the 24 months visit in the previous study. - The eyes of subjects must have transparency to permit visualization of parts inside the eye such as the retina and subjects must be able to look steadily at a provided target allowing the doctor to get good quality pictures from the eye. - Female subjects must be: - Women that cannot have children, or - Women who can have children must have a negative result of a blood pregnancy test on the first day of the study visit and agree to use ways to avoid pregnancy during the study and 90 days after the last dose of the study medication. - Males with female partners who can get pregnant must also agree to use ways to avoid pregnancy and agree not to donate sperm while in the study or until 90 days after administering the last dose of the study medication. - Agree to participate in the study by signing the consent document providing information about the study; and take part in all tests and assessments as required. Exclusion Criteria: Subjects cannot take part in the study if the eye that will be treated during the study currently meets any of the following conditions: - Participants in APL2 303/304 studies who fully stopped study drug treatment before the visit in month 24 but remain in the study to observe the study medication's safety. Those subjects who temporarily paused study drug treatment are still eligible to participate. - If, according to your doctor you currently have any disease affecting your eyes that could interfere with your vision, including diseases that affect your retina or macula (the center of the back of your eyes). And, if according to your doctor, the disease in your eyes is benign and does not interfere with the study (e.g. diseases that affects the periphery of the retina), you are also eligible to take part in the study. - If, according to your doctor you currently have any inflammation/infection in or around your eyes that could prohibit you from receiving an injection inside your eyes. - If, according to your doctor, any current disease that could directly interfere in your participation in the study or that could make it difficult for you to come to the scheduled visits during the next three yearsover the next 36 months. - If you have known allergies to fluorescein sodium, a solution that is injected into your body for eye testing; or to pegcetacoplan (the study drug) or any inactive substances in pegcetacoplan solution. - If you currently are pregnant, breastfeed or have a positive pregnancy test.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PEGCETACOPLAN (APL-2)
Complement (C3) Inhibitor

Locations

Country Name City State
Argentina Centro Oftalmologico Dr. Charles S.A. Buenos Aires
Argentina Diagnostico Ocular Buenos Aires
Argentina Fundacion Zambrano Buenos Aires
Argentina Organizacion Medica de Investigacion (OMI) Buenos Aires
Argentina Instituto Oftalmologico de Cordoba Córdoba
Argentina OFTAR Mendoza
Argentina Microcirujia Ocular Rosario Rosario
Argentina Oftalmologos Especialistas Santa Fe
Australia Centre for Eye Research Australia East Melbourne Victoria
Australia Retina and Eye Consultantss Hurstville
Australia Lions Eye Institute Nedlands
Australia Marsden Eye Specialist Parramatta New South Wales
Australia Strathfield Retina Clinic Strathfield New South Wales
Australia Sydney Retina Sydney New South Wales
Australia Save Sight Institute Westmead
Australia The Ashley Centre Westmead New South Wales
Brazil IPEPO Instituto Da Visao São Paulo
Canada Ivey Eye Institute London Ontario
Canada Retina Centre of Ottawa Ottawa Ontario
Canada University of Ottawa Eye Institute Ottawa Ontario
Czechia Fakultni Nemocnice Ostrava Ostrava-Poruba
Czechia AXON Clinical, s.r.o. Prague
Czechia University hospital Kralovske Vinohrady Prague
Czechia Vseobecna fakultni nemocnice v Praze Praha
Czechia Gemini Eye Clinic Zlín
France CHU de Bordeaux Bordeaux
France Centre Hospitalier Intercommunal de Creteil Créteil cedex
France CHU Dijon Dijon
France Clinique du Val d'Ouest Écully
France Hopital de la Croix-Rousse Lyon
France Centre monticelli Paradis Marseille
France CHU de Nantes - Hotel Dieu Nantes Cedex
France Centre Ophtalmo. Image/Laser Paris
France Centre Ophtalmol de l Odeon Paris
France CHNO des Quinze-Vingts Paris
France Hopital Lariboisiere Paris
France Centre ophtalmologique Saint-Exupery Saint-Cyr-sur-Loire Lyon
France CHU de Strasbourg Hopital Civil Strasbourg
France Maison Rouge Ophthalmologic Center Strasbourg
Germany Universitats-Augenklinik Bonn Bonn
Germany Uniklinik Koln Cologne
Germany University Opthalmology Clinic Freiburg im Breisgau
Germany Uni-medizin Gottingen Augenklinik 3.B1.261 Göttingen
Germany Universitatsklinikum Schleswig-Holstein Lübeck
Germany Klinikum der Stadt Ludwigshafen gGmbH Ludwigshafen
Germany Augenklinik der LMU Munchen München
Germany Klinikum rechts der Isar München
Germany Augenzentrum am St. Franziskus-Hospital Münster
Germany Universitatsklinikum Munster Münster
Germany Universitatsklinikum Regensburg Münster
Germany STZ Eyetrial Tübingen
Israel Assaf ha Rofeh MC Be'er Ya'akov
Israel Rambam Health Care Campus Haifa
Israel Hadassah Medical Center Jerusalem
Israel Tel Aviv Sourasky Medical Center Tel Aviv
Italy ASST Fatebenefratelli-Sacco Ospedale Luigi Sacco Milano
Italy IRCCS San Raffaele Milano
Netherlands Academisch Medisch Centrum Amsterdam
Netherlands Radboud university medical center Oogheelkunde Nijmegen
New Zealand Southern Eye Specialists Christchurch
New Zealand Hamilton Eye Clinic Hamilton
Poland Eye Surgery Center Professor Zagorski Bydgoszcz
Poland Oftalmika Eye Hospital Bydgoszcz
Poland Grupo Laser Vision Rzeszów
Poland Oculomedica Eye Centre Tarnów
Poland UNO-MED Centrum Medyne Tarnów
Spain Hospital Universitario Puerta de Hierro Madrid
Spain Instituto Oftalmologico Gomez-Ulla Santiago De Compostela
United Kingdom Bristol Eye Hospital Bristol
United Kingdom Huddersfield Royal Infirmary Huddersfield West Yorkshire
United Kingdom St James's University Hospital Leeds West Yorkshire
United Kingdom Royal Liverpool University Hospital Liverpool
United Kingdom Kings College Hospital NHS Trust London
United Kingdom London Vision Clinic London
United Kingdom Oxford Eye Hospital Oxford
United Kingdom Sunderland Eye Infirmary Sunderland
United States Vision Research Center Eye Associates of NM Albuquerque New Mexico
United States Michigan Medicine Kellogg Eye Center Ann Arbor Michigan
United States Western Carolina Retinal Associates Asheville North Carolina
United States Southeast Retina Center, PC Augusta Georgia
United States Retina Research Center PLLC Austin Texas
United States California Retina Consultants Bakersfield California
United States Elman Retina Group Baltimore Maryland
United States The Retina Care Center Baltimore Maryland
United States Brown Retina Institute Bellaire Texas
United States Vitreoretinal Associates of Washington Bellevue Washington
United States Mid Atlantic Retina Bethlehem Pennsylvania
United States Retina Center of NJ, LLC Bloomfield New Jersey
United States Gailey Eye Clinic Retina Center Bloomington Illinois
United States Ophthalmic Consultants of Boston Boston Massachusetts
United States Tufts Medical Center Boston Massachusetts
United States Florida Eye Microsurgical Institute, Inc. Boynton Beach Florida
United States Retinal Diagnostic Center Campbell California
United States Charlotte Eye Ear Nose and Throat Associates, PS Charlotte North Carolina
United States University of Virginia Charlottesville Virginia
United States The Retina Group of Washington Chevy Chase Maryland
United States Northwestern Feinberg School of Medicine Chicago Illinois
United States Rush University Medical Center Chicago Illinois
United States Blue Ocean Clinical Research Clearwater Florida
United States Cleveland Clinic Cole Eye Institute Cleveland Ohio
United States Retina Associates of Cleveland Cleveland Ohio
United States Retina Associates of Cleveland, Inc. Cleveland Ohio
United States The Ohio State University Columbus Ohio
United States Texas Retina Associates Dallas Texas
United States Danbury Eye Physicians & Surgeons, PC Danbury Connecticut
United States Southwest Retina Research Center, LLC Durango Colorado
United States Duke University, Duke Eye Center Durham North Carolina
United States Retina Vitreous Center, PLLC Edmond Oklahoma
United States The Retina Partners Encino California
United States Oregon Retina LLP Eugene Oregon
United States The Retina Group of Washington Fairfax Virginia
United States Emerson Clinical Research Institute Falls Church Virginia
United States Pinnacle Research Insitute Fort Lauderdale Florida
United States National Opthalmic Research Institute Fort Myers Florida
United States Retina Health Center Fort Myers Florida
United States Retina Consultants of Orange County Fullerton California
United States Charles Retina Institute Germantown Tennessee
United States Associated Retinal Consultants, PC Grand Rapids Michigan
United States Long Island Vitreoretinal Consultants Great Neck New York
United States Cumberland Valley Retina Center Hagerstown Maryland
United States Mid Atlantic Retina Specialist Hagerstown Maryland
United States Graystone Eye Hickory North Carolina
United States Houston Eye Associates Houston Texas
United States Retina Consultants of Houston, PA Houston Texas
United States Atlantis Eyecare Huntington Beach California
United States Midwest Eye Institute Indianapolis Indiana
United States Jacobs Retina Center, UCSD La Jolla California
United States Retina and Vitreous Associates of Kentucky, PSC dba Retina Associates of Kentucky Lexington Kentucky
United States Doheny Eye Center UCLA Los Angeles California
United States Retina Health Center Madison Wisconsin
United States Retina-Vitreous Associates Medical Group Madison Wisconsin
United States Sara Gater Manchester New Hampshire
United States Georgia Retina, PC Marietta Georgia
United States Valley Retina Institute McAllen Texas
United States Bascom Palmer Eye Institute Miami Florida
United States Vitreoretinal Surgery Minneapolis Minnesota
United States Retina Vitreous Consultants Monroeville Pennsylvania
United States Northern California Retina Vitreous Associates Mountain View California
United States Retina Associates of Utah, PC Murray Utah
United States Bascom Palmer Eye Institute at Naples Naples Florida
United States Tennessee Retina, PC Nashville Tennessee
United States Vitreous Retina Macula Consultants of New York New York New York
United States Ophthalmic Consultants of Long Island Oceanside New York
United States Palm Beach Gardens Palm Beach Gardens Florida
United States Retina Institute of California Medical Group Palm Desert California
United States Byers Eye Institute, Stanford University Palo Alto California
United States Retina Specialty Institute Pensacola Florida
United States Mid Atlantic Retina Philadelphia Pennsylvania
United States Mid Atlantic Retina Philadelphia Pennsylvania
United States Associated Retina Consultants, Ltd. Phoenix Arizona
United States Retinal Research Institue, LLC Phoenix Arizona
United States Eye Associates of Pinellas Pinellas Park Florida
United States Eye Health Northwest Portland Oregon
United States Retina Northwest, PC Portland Oregon
United States Retina Consultants San Diego Poway California
United States Black Hills Regional Eye Institute Rapid City South Dakota
United States Sierra Eye Associates Reno Nevada
United States University of Utah - John A. Moran Center Salt Lake City Utah
United States Medical Center Ophthalmology Associates San Antonio Texas
United States Retina Associates of South Texas San Antonio Texas
United States Orange County Retina Medical Group Santa Ana California
United States California Retina Consultants Santa Barbara California
United States Spokane Eye Clinical Research Spokane Washington
United States New England Retina Consultants, PC Springfield Massachusetts
United States East Florida Eye Institute Stuart Florida
United States Retina Associates of Florida Tampa Florida
United States University of South Florida Tampa Florida
United States NJ Retina Teaneck New Jersey
United States Retina Consultants of Houston The Woodlands Texas
United States NJ Retina Toms River New Jersey
United States Associated Retinal Consultants, PC Traverse City Michigan
United States Bay Area Retina Associates Walnut Creek California
United States Retina Group of New England - New London Waterford Connecticut
United States AIO Visionary Eye Care West Mifflin Pennsylvania
United States Center for Retina and Macular Disease Winter Haven Florida
United States Retina Associates of Cleveland, Inc. Youngstown Ohio

Sponsors (1)

Lead Sponsor Collaborator
Apellis Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Brazil,  Canada,  Czechia,  France,  Germany,  Israel,  Italy,  Netherlands,  New Zealand,  Poland,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of ocular and systemic adverse events Up to 36 Months
Secondary Change from baseline in the total area of GA lesion(s) in the study eye (in mm2) The total area of GA lesion(s) in the study eye (in mm2) as assessed by FAF at Month 12, Month 24, and Month 36 Up to 36 Months
Secondary Change from baseline in NL-BCVA score (study eye) NL-BCVA score as assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) chart at Month 12, Month 24, and Month 36 Up to 36 Months
Secondary Change from baseline in LL-BCVA score (study eye) LL-BCVA score as assessed by ETDRS chart at Month 12, Month 24, and Month 36 Up to 36 Months